<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597713</url>
  </required_header>
  <id_info>
    <org_study_id>NN1954-3936</org_study_id>
    <secondary_id>2011-005147-27</secondary_id>
    <secondary_id>U1111-1125-2969</secondary_id>
    <nct_id>NCT01597713</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects</brief_title>
  <official_title>A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the safety,
      tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of
      NNC 0148-0000-0362 as tablets in healthy volunteers.

      The trial consists of two parts. In part 1, single escalating doses of NNC 0148-0000-0362,
      placebo or insulin glargine is given. In part 2, subjects will receive single doses of NNC
      0148-0000-0362 administered orally or intravenously.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Recorded from trial product administration and until completion of Sub-visit G (i.e. Day 13) of the dosing visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin concentration-time curve (with Trial part 1)</measure>
    <time_frame>From 0 to 288 hours after a single oral dose of NNC 0148-0000-0362 or a single subcutaneous (s.c.) dose of insulin glargine, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate (GIR)-time curve (Trial part 1)</measure>
    <time_frame>From 0 to 24 hours after a single oral dose of NNC 0148-0000-0362 or a single s.c. dose of insulin glargine, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin concentration-time curve (Trial part 2)</measure>
    <time_frame>From 0 hours to infinity after a single dose of NNC 0148-0000-0362 administered orally as 1 and 3 tablets and intravenously, respectively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1, level 1-7 escalating doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, cross-over</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0148-0000-0362</intervention_name>
    <description>Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group</description>
    <arm_group_label>Part 1, level 1-7 escalating doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group</description>
    <arm_group_label>Part 1, level 1-7 escalating doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will receive a single dose of oral placebo within each dose group</description>
    <arm_group_label>Part 1, level 1-7 escalating doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0148-0000-0362</intervention_name>
    <description>Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period</description>
    <arm_group_label>Part 2, cross-over</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0148-0000-0362</intervention_name>
    <description>Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period</description>
    <arm_group_label>Part 2, cross-over</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0148-0000-0362</intervention_name>
    <description>Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period</description>
    <arm_group_label>Part 2, cross-over</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 18-28 kg/m^2 (both inclusive)

          -  Subject who is considered to be healthy based on the medical history, physical
             examination, and the results of vital signs, electrocardiogram (ECG) and clinical
             laboratory tests performed during the screening visit, as judged by the investigator

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Previous participation in this trial. Participation is defined as randomised

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the
             investigator

          -  Any chronic disorder or severe disease which, in the opinion of the investigator,
             might jeopardise subject's safety or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

